IDWeek 2023: Tripledemic Viruses Under the Microscope

The Patient Care editors searched the IDWeek program for symposia, oral abstracts, late breaking clinical trials, and poster sessions where data and updates on the 3 tripledemic hot-topic viruses –COVID-19, respiratory syncytial virus, and influenza – will be presented and discussed.

Following is a sampling of what we found in each category. Scroll through the lists for an orientation, then click on the link at the end for detailed information on day, time, and location.

INFLUENZA

1101 - Antiviral Prescription in Children with Influenza in Emergency Departments (ED): New Vaccine Surveillance Network (NVSN), 2016–2020

1104 - Characteristics and Seasonality of Children Hospitalized with Parainfluenza Virus Infections (PIV), including PIV-4, New Vaccine Surveillance Network, 2016–2020

1105 - Clinical outcomes in non-pregnant adults aged ≥18 years hospitalized with laboratory-confirmed RSV infection, 12 U.S. states, October 2014–April 2022

1108 - Severity of Illness among Adults Hospitalized with Respiratory Syncytial Virus Compared with COVID-19 and Influenza — IVY Network, 25 Hospitals, 20 U.S. States, January 31, 2022 – April 11, 2023

1122 - Parainfluenza Virus Co-detection With Respiratory Syncytial Virus or Influenza is Associated with Higher Odds of Hospitalization in Children < 2 Years Old, New Vaccine Surveillance Network (NVSN), 2016–2020

1941 - Coadministration of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine with Influenza Vaccine in Older Adults

2074 - Longitudinal wastewater surveillance for endemic respiratory viruses and its correlation with clinically confirmed cases in Calgary, Canada.

2089 - Coadministration of Intranasal M2SR (M2-deficient Single Replication) Investigational Influenza Vaccine with Fluzone High Dose Induces Superior Immune Responses to Fluzone High Dose Alone in 65–85-Year-Old Adults

2093 - Effectiveness of Influenza Vaccination Against Influenza-Associated Emergency Department (ED) Visits and Hospitalizations Among Children with and Without Underlying Medical Conditions, New Vaccine Surveillance Network (NVSN), 2015-2016 through 2019-2020 Influenza Seasons

2095 - Multisite Derivation and Validation of Machine Learning Models to Predict Severe Influenza Outcomes in Emergency Department Patients

2096 - Incidence of Influenza-Related Medical Encounters Among Adults in The United States During the 2015-2020 Influenza Seasons

Respiratory Syncytial Virus

89 - The Impact of Nirsevimab on an RSV Season in All Infants: Data from The HARMONIE Study

AE-27 - A Newly Approved Respiratory Syncytial Virus (RSV) Vaccine to Help Protect Adults 60 Years and Older

AE-29 - Navigating RSV in Adults: Insights into Disease and Vaccination

1019 - Respiratory Syncytial Virus (RSV) Diagnoses in Hospitalized Patients Increases when Additional Specimen Types are Added to Nasopharyngeal Swab: Results from the RSV in Adults Multispecimen Study

1105 - Clinical outcomes in non-pregnant adults aged ≥18 years hospitalized with laboratory-confirmed RSV infection, 12 U.S. states, October 2014–April 2022

“Key Updates and Challenges in the Management of RSV and Other Respiratory Viruses in the Immunocompromised: An Expert Discussion and Real-World Experience.”

1934 - Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)

1936 - Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons

1940 - Real-Life Impact of Pneumococcal Conjugate Vaccines (PCVs) on Hospitalization of Young Children with RSV-Associated Community-acquired Alveolar Pneumonia (CAAP)

2099 - The Transfer of Maternal Antibodies and Dynamics of Maternal and Natural Infection-induced Antibodies against RSV in Children: A Longitudinal Cohort Study

COVID-19

1935 - COVID-19 mRNA Vaccination Reduces the Occurrence of Post-COVID Conditions in U.S. Children Aged 5-17 Years Following Omicron SARS-CoV-2 Infection, July 2021-September 2022

1937 - Use of Paxlovid for Treatment of Acute COVID-19 and Occurrence of Post-COVID Conditions among Children and Adults at High-Risk for Severe COVID-19, April 1 - December 31, 2022.

1938 - CoviLiv™, a Novel Intranasal Live-Attenuated COVID-19 Vaccine Candidate, Induces Robust Humoral and Cellular Immunity in First-In-Human Clinical Trial CDX-CoV-001

221 - What's Still Happening in COVID-19 Prevention?

Maternal hybrid immunity to SARS-CoV-2 during pregnancy provides more durable infant antibody responses compared to natural

Reduced risk of SARS-CoV-2 infection among household contacts with hybrid immunity from recent COVID-19 vaccination and SARS-CoV-2 infection

COVID-19 mRNA Vaccine Effectiveness against Hospitalizations among U.S. Children and Adolescents During Omicron Variant Predominance

Effectiveness of Bivalent mRNA Vaccines in Preventing SARS-CoV-2 Infection Among Children Aged 5-17 years: an Evaluation of Multicenter Prospective Cohorts, United States, September 2022 - January 2023

Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023

Click here for more Patient Care coverage of IDWeek 2023 news.